Analysis on efficacy and safety of Adefovirdipivoxil therapy for patients with HBeAg(+) chronic hepatitis B resistant to Lamivudine

Objective To observe and analyze the efficacy and safety of adefovirdipivoxil(ADV) therapy for patients with HbeAg(+) chronic hepatitis B resistant to lamivudine(LAM).Methods Seventy six patients with HbeAg(+) chronic hepatitis B resistant to LAM were treated with ADV and LAM respectively in this hospital during the period of June,2006 to June,2007.Serum levels of ALT,HBeAg and HBV DNA were measured after a therapeutic course of 1 year.Moreover,the adverse events were recorded at the same time.Results There was no significant difference in sero-conversion rate of HBeAg between these two groups(P0.05) after a therapeutic course of 1 year,while the rate of normalization of ALT level in ADV group was significantly higher than that of LAM group(P0.05).HBV DNA level in ADV group was decreased and it was significantly lower than that of LAM group(P0.05).There was no teratogenesis occurred in patients after ADV and LAM treatment for 1 year.Conclusion ADV is safe and efficacious in treatment of patients with HBeAg(+) chronic hepatitis B resistant to LAM.